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Receptor tyrosine kinases of the Eph family bind to cell surface-associated ephrin ligands on 
neighboring cells. The ensuing bidirectional signals have emerged as a major form of contact-
dependent communication between cells. New findings reveal that Eph receptors and ephrins 
coordinate not only developmental processes but also the normal physiology and homeostasis 
of many adult organs. Imbalance of Eph/ephrin function may therefore contribute to a variety 
of diseases. The challenge now is to better understand the complex and seemingly paradoxical 
signaling mechanisms of Eph receptors and ephrins, which will enable effective strategies to target 
these proteins in the treatment of diseases such as diabetes and cancer.Eph-Ephrin Bidirectional Signaling
Since its discovery two decades ago, the Eph family of receptor 
tyrosine kinases has been implicated in an increasing number 
of physiological and pathological processes in many cell types 
and different organs. Therefore, elucidating the mechanism 
of action of the Eph receptors and their signaling networks is 
important for understanding developmental processes, the 
physiology of adult organs and, as is becoming increasingly 
evident, the pathogenesis of many diseases. Eph receptors 
have diverse activities, including widespread effects on the 
actin cytoskeleton, cell-substrate adhesion, intercellular junc-
tions, cell shape, and cell movement (Egea and Klein, 2007; 
Himanen et al., 2007; Pasquale, 2005). In addition, effects on 
cell proliferation, survival, differentiation, and secretion have 
also been described. These activities depend on the interaction 
of the Eph receptors with the ephrins (Eph receptor interacting 
proteins). In the human genome, there are nine EphA recep-
tors that bind to five GPI-linked ephrin-A ligands and five EphB 
receptors that bind to three transmembrane ephrin-B ligands. 
Interactions are promiscuous within each class, and some Eph 
receptors can also bind to ephrins of the other class.
Several of the domains in the Eph receptor extracellular region 
can bind to the ephrins. The amino-terminal “ephrin-binding” 
domain contains a high-affinity binding site that mediates recep-
tor-ephrin interaction between cells (Figure 1) (Himanen et al., 
2007; Wimmer-Kleikamp and Lackmann, 2005). Two additional 
lower-affinity ephrin-binding sites have also been identified in the 
ephrin-binding domain and the cysteine-rich region, which are 
thought to facilitate clustering of multiple Eph-ephrin complexes. 
The Eph fibronectin type III domain closer to the membrane can 
also bind to ephrins, if they are located on the same cell surface.
Downstream Signaling
A distinctive feature of Eph-ephrin complexes is their ability 
to generate bidirectional signals that affect both the recep-
tor-expressing and ephrin-expressing cells (Pasquale, 2005). 
Eph receptor “forward” signaling depends on the tyrosine 38 Cell 133, April 4, 2008 ©2008 Elsevier Inc.kinase domain, which mediates autophosphorylation as well 
as phosphorylation of other proteins, and on the associa-
tions of the receptor with various effector proteins. Ephrin-B 
“reverse” signaling also depends in part on tyrosine phos-
phorylation of the ephrin cytoplasmic region (mediated by 
Src family kinases and some receptor tyrosine kinases) and 
on associated proteins. Most Eph receptors and the B-type 
ephrins also have a carboxy-terminal PDZ domain-binding 
site, which is particularly important for the physiological 
functions of ephrin-B (Egea and Klein, 2007). The mecha-
nisms of reverse signaling for ephrin-A are less understood, 
but these GPI-linked ephrins probably use associated trans-
membrane proteins to fulfill their signaling function. Several 
candidates have been reported at meetings, including the 
p75 low-affinity nerve growth factor receptor (T.R. McLaugh-
lin et al., 2007, Soc. Neurosci., abstract).
Eph receptors and ephrins use some common signal-
ing effectors, such as Src family kinases and Ras/Rho fam-
ily GTPases, which are particularly important for the organi-
zation of the actin cytoskeleton and cell adhesion (Figure 1). 
Some signaling connections may apply only to a particular 
Eph class, including those between EphA receptors and the 
Rho exchange factor Ephexin or between EphB receptors 
and the exchange factors Intersectin and Kalirin. Others are 
more selective. For example, the lipid phosphatase Ship2 was 
found to interact only with EphA2, and the GTPase-activating 
proteins SPAR/E6TP1 interacted only with EphA4 and EphA6 
among several EphA and EphB receptors examined (Richter et 
al., 2007; Zhuang et al., 2007).
An emerging theme is that Eph receptors and ephrins 
activate complex bidirectional signaling networks that often 
include signaling pathways with opposite effects (Figure 1). 
This may explain why differences in cellular context can dra-
matically alter the outcome of Eph/ephrin stimulation. Fur-
thermore, the degree of Eph/ephrin clustering may not only 
affect signal strength but may also differentially regulate 
downstream pathways thus leading to variable outcomes 
(Pasquale, 2005; Poliakov et al., 2004). Further increasing 
versatility, forward and reverse signaling can also be inde-
pendently regulated, for example through Eph receptor 
dephosphorylation (Konstantinova et al., 2007). In addition, 
interactions between Eph receptors and ephrins located on 
the same cell surface appear to represent a mechanism for 
silencing bidirectional signaling, although it is unclear under 
what circumstances Eph receptors and ephrins intermin-
gle rather than segregate in different microdomains of the 
plasma membrane (Egea and Klein, 2007).
Processing of Eph-Ephrin Complexes
A well-characterized effect of Eph forward signaling is retrac-
tion of the cell periphery following contact with ephrin-
expressing cells (Pasquale, 2005). This repulsive response 
is particularly important for axon guidance and sorting of 
Eph-expressing cells from ephrin-expressing cells dur-
ing development. Several mechanisms can explain how the 
initial adhesive contact evolves into cell separation. One is 
removal of the adhesive Eph-ephrin complexes from the cell 
surface by endocytosis of vesicles containing plasma mem-
brane fragments derived from both cells (Egea and Klein, 
2007). An implication of this unusual mechanism is that the 
two cells exchange Eph receptors or ephrins and possi-
bly their associated proteins, which may continue to signal 
from intracellular compartments. Another way to convert cell 
adhesion into repulsion is proteolytic cleavage (Egea and 
Klein, 2007; Himanen et al., 2007). Studies have shown that 
metalloproteases and other proteases can cleave the extra-
cellular portions of EphB receptors and ephrins. The remain-
ing membrane-anchored fragments are further cleaved by 
γ-secretase, followed by proteasomal degradation.
Proteolytic cleavage not only terminates the adhesive 
Eph-ephrin interaction and causes downregulation of the 
proteins, but it can also generate Eph/ephrin fragments with 
new activities. For example, the ephrin-B cytoplasmic pep-
Figure 1. Eph Receptor-Ephrin Bidirectional Pathways Regulate 
GTPases
(A) Regulation of Ras GTPases. (B) Regulation of Rho GTPases. The domain 
structure of an Eph receptor is shown schematically, including from the N 
terminus: ephrin-binding domain, cystein-rich region, two fibronectin type III 
domains, transmembrane segment, juxtamembrane domain, kinase domain, 
SAM domain, and PDZ domain-binding site. The domain structure of an eph-
rin-B ligand is also shown, including the Eph-binding domain, linker region, 
transmembrane segment, cytoplasmic region, and PDZ domain-binding site. 
The pathways shown have been characterized with one or several Eph recep-
tors/ephrins. For example, in (A) Shp2 has been linked to EphA2; Shc-Grb2 
to EphA2 and EphB1; Cas-Rap1 to EphB1; and SPAR/E6TP1 to EphA4 and 
EphA6. In (B), α2-chimaerin has been linked to EphA4; FAK to EphA2 and 
EphB2; Ship2 to EphA2; Abl-Crk to EphB4; Ephexin family members to EphA 
receptors; and Kalirin, Tiam1, and Intersectin to EphB receptors. Tyrosine 
phosphorylation is shown only for some effectors where it has a demonstrat-
ed role in Eph-ephrin bidirectional signaling. The location of the arrows does 
not imply the involvement of a particular Eph or ephrin domain. The relative 
activation of different pathways and their effects on cell behavior may depend 
on the ephrin levels, degree of receptor clustering, and cellular context. The 
question marks indicate signaling connections that have not been conclu-
sively demonstrated downstream of Eph receptors or ephrins. PIP3, phos-
phatidylinositol (3,4,5) phosphate; GEF, guanine nucleotide exchange factor; 
LMW-PTP, low-molecular-weight phosphotyrosine phosphatase.Cell 133, April 4, 2008 ©2008 Elsevier Inc. 39
tide released by γ-secretase activates the tyrosine kinase 
Src, which in turn phosphorylates the cytoplasmic domain 
of intact B-type ephrins and perhaps other substrates (Egea 
and Klein, 2007). Furthermore, the soluble Eph and ephrin 
extracellular portions released by metalloproteases might 
reach distant cells and trigger effects that are independent 
of cell-cell contact. They could, for example, function as 
monomeric inhibitors of bidirectional signaling. Alternatively, 
soluble A-type ephrins oligomerized by transglutamination 
may serve to activate EphA receptors at a distance (Alford 
et al., 2007).
Crosstalk with Other Signaling Systems
Although bidirectional signaling is their best characterized 
modus operandi, Eph receptor and ephrins may also func-
tion independently of each other and/or in concert with other 
cell-surface communication systems (Figure 2). For example, 
recent studies have proposed that members of the epider-
mal growth factor (EGF) receptor family can coopt EphA2 
as an effector to promote cell motility and proliferation, per-
haps independently of ephrin stimulation (Brantley-Sieders 
et al., 2008; Larsen et al., 2007). Other studies have shown 
association and synergistic responses of fibroblast growth 
factor (FGF) receptors and EphA4, and that phosphorylation 
by FGF receptors inhibits ephrin-B1 activities (Arvanitis and 
Davy, 2008). Intricate links between EphB/ephrin-B and Wnt 
signaling have also been revealed in different model sys-
tems. EphB receptors and Ryk, a Wnt receptor containing 
an inactive tyrosine kinase domain, can physically associ-
ate and likely function together in craniofacial development 
and axon guidance (Arvanitis and Davy, 2008; Schmitt et al., 
2006). Furthermore, both EphB receptors and B-type eph-
rins can signal through components of the noncanonical Wnt 
pathway (Figure 1B) (Kida et al., 2007; Lee et al., 2006). This 
pathway in turn causes endocytic removal of EphB  receptors 
Figure 2. Crosstalk between Eph-Ephrins and Other Receptors
Some forms of crosstalk occur at epithelial cell junctions, others have been 
reported in neurons and other cell types. RTK, receptor tyrosine kinase; yellow 
circles, tyrosine phosphorylation; the scissors indicate proteolytic cleavage.40 Cell 133, April 4, 2008 ©2008 Elsevier Inc.from the cell surface, whereas canonical Wnt signaling 
upregulates EphB transcripts and downregulates ephrin-B 
transcripts (Clevers and Batlle, 2006; Kida et al., 2007).
E-cadherin-dependent intercellular adhesion can also reg-
ulate Eph receptor expression, cell-surface localization, and 
ephrin-dependent activation (Arvanitis and Davy, 2008; Ireton 
and Chen, 2005). The regulation is reciprocal, and EphB sig-
naling drives E-cadherin to the cell surface thus promoting 
the formation of epithelial adherens junctions and enabling 
EphB/ephrin-B-dependent cell sorting. Conversely, inhibiting 
EphB-ephrin-B binding was found to disturb adherens junc-
tions (Cortina et al., 2007; Noren and Pasquale, 2007). EphA2 
overexpression, on the other hand, has been shown to desta-
bilize adherens junctions through a pathway involving Src, 
the low-molecular-weight phosphotyrosine phosphatase, and 
p190RhoGAP, resulting in increased RhoA activity (Figure 1B) 
(Fang et al., 2008). The Eph system also affects integrin-me-
diated cell communication with the extracellular environment 
(Bourgin et al., 2007; Pasquale, 2005; Wimmer-Kleikamp and 
Lackmann, 2005).
Crosstalk of EphA2 or ephrin-B1 with claudins, which are 
components of epithelial tight junctions, has been implicated 
in the regulation of cell adhesion and intercellular permeabil-
ity (Arvanitis and Davy, 2008). Some claudins can also cause 
ephrin-B1 tyrosine phosphorylation independently of EphB 
receptors. Gap junction proteins are also critical for Eph/eph-
rin function in cell sorting, insulin secretion, and osteogenic 
differentiation (Davy et al., 2006; Konstantinova et al., 2007; 
Poliakov et al., 2004).
Reciprocal communication also occurs between EphB recep-
tors and calcium channels (Figure 2). Following ephrin binding, 
EphB2 associates with the NMDA receptors, which are calcium 
channels, and promotes clustering of these neurotransmitter 
receptors at synapses (Yamaguchi and Pasquale, 2004). More-
over, activation of Src family kinases downstream of EphB2 
leads to NMDA receptor phosphorylation, which increases 
NMDA-dependent calcium influx. Interestingly, increased 
intracellular calcium in turn promotes proteolytic degradation 
of EphB2, demonstrating that Eph levels can be regulated by 
intracellular calcium independently of ephrin binding (Litterst 
et al., 2007).
More information on Eph signaling mechanisms and cross-
talk with other signaling systems can be found in recent reviews 
(Arvanitis and Davy, 2008; Egea and Klein, 2007; Himanen et 
al., 2007; Noren and Pasquale, 2004; Pasquale, 2005; Poliakov 
et al., 2004).
Neural Development, Plasticity, and Regeneration
The activities of Eph receptors and ephrins in the nervous 
system have been extensively studied. Neurons form com-
plex networks where electrical signals travel from axonal to 
dendritic processes through specialized junctions called syn-
apses. Here, neurotransmitters released from the presynaptic 
terminal in response to electrical signals activate postsynaptic 
ion channel receptors that initiate new electrical and chemi-
cal signals in the postsynaptic neuron. The network of neu-
ronal processes is embedded among surrounding glial cells, 
which regulate many properties of the neurons including their 
ability to form synapses. Eph-ephrin bidirectional signaling is 
important not only for the communication between neurons 
but also for that between neurons and glial cells (Yamaguchi 
and Pasquale, 2004).
Development of Neuronal Connections
Eph receptors and ephrins are highly expressed in the devel-
oping nervous system, where they have well-known roles in 
the establishment of neuronal connectivity by guiding axons 
to the appropriate targets and regulating the formation of 
synaptic connections. The trajectories of many axonal pro-
jections depend on Eph receptors and ephrins distributed in 
gradients or forming boundaries (Luo and Flanagan, 2007; 
Pasquale, 2005; Poliakov et al., 2004). A number of Ras/Rho 
regulatory proteins have been implicated over the years in 
axon guidance by the Eph receptors, including several gua-
nine nucleotide exchange factors for Rho GTPases (Figure 
1B). Only recently four simultaneous studies have also impli-
cated a GTPase-activating protein for Rac1, α2-chimaerin, 
as a critical EphA4 effector (Beg et al., 2007; Iwasato et al., 
2007; Shi et al., 2007; Wegmeyer et al., 2007). Remarkably, 
α2-chimaerin mutant mice have defects in the formation of 
cortical and spinal motor circuits that phenocopy those in 
the EphA4 knockout mice, indicating that α2-chimaerin is 
essential for certain axon guidance decisions that depend 
on EphA4. Mice lacking the adaptor proteins Nck1 and Nck2 
in the nervous system also exhibited similar defects, sug-
gesting that Nck adaptors, which can bind both EphA4 and 
α2-chimaerin, may also play a role in the pathway (Fawcett et 
al., 2007; Wegmeyer et al., 2007).
In vitro and in vivo analyses of hippocampal and cortical 
neurons have revealed that the EphB receptors and B-type 
ephrins regulate multiple steps in the assembly and matura-
tion of the pre- and postsynaptic sides of excitatory syn-
apses. Interestingly, different Eph receptor domains can 
control different aspects of synaptogenesis. The EphB2 
extracellular region, for example, is sufficient to promote the 
assembly of presynaptic structures even when expressed 
in non-neuronal cells (Kayser et al., 2006). This activity 
requires the ephrin-binding domain, suggesting a trans-syn-
aptic interaction with axonal ephrins. This ability of EphB2 
to promote presynaptic specializations, however, may vary 
in different brain regions because it was detected in cortical 
but not hippocampal neurons. Activation of ephrin-B reverse 
signaling by postsynaptic EphB2 has also been recently 
implicated in the morphological and functional maturation of 
developing retinotectal synapses in the Xenopus optic tec-
tum (Lim et al., 2008). The EphB2 extracellular portion also 
associates with NMDA neurotransmitter receptors and pro-
motes their clustering at synapses following ephrin-B stim-
ulation (Dalva et al., 2007). Furthermore, EphB2 promotes 
AMPA neurotransmitter receptor clustering and endocy-
tosis, and these activities respectively depend on the PDZ 
domain-binding site of EphB2 and its kinase activity.
Most excitatory synapses are located on small dendritic 
protrusions called dendritic spines, which compartmen-
talize the postsynaptic space from the dendritic shaft, but 
some are also located on the dendritic shaft (Dalva et al., 
2007; Yamaguchi and Pasquale, 2004). EphB receptors selectively promote the formation of the synapses located 
on spines and also play a critical role in spine maturation, 
which results in the characteristic mushroom shape deter-
mined by the actin cytoskeleton. Studies with cultured neu-
rons have implicated several nucleotide exchange factors 
for Rho GTPases in EphB-dependent spine elaboration, 
including Kalirin, Intersectin, and Tiam1 (Figure 1B) (Tolias 
et al., 2007; Yamaguchi and Pasquale, 2004). It is not known 
whether these exchange factors function in different sub-
sets of dendritic spines and whether there are differences in 
their effects on the spines.
Ephrin-B ligands are also found postsynaptically, and 
ephrin-B3 expressed in non-neuronal cells can drive the for-
mation of presynaptic structures in cocultured neurons, pre-
sumably by interacting with axonal Eph receptors (Aoto et al., 
2007). Interestingly, ephrin-B3 overexpression and knock-
down using short-interfering RNAs (siRNAs) in cultured hip-
pocampal neurons have shown that the excitatory synapses 
induced by ephrin-B3 are located on the dendritic shaft. 
Consistent with this, the ephrin-B3 knockout mice have fewer 
shaft synapses in hippocampal area CA1 than wild-type mice. 
The synaptogenic activity of ephrin-B3 depends on the scaf-
folding protein GRIP1, which may help ephrin-B3 clustering 
by interacting with its PDZ domain-binding site. Treatment of 
cultured hippocampal neurons with EphB2 Fc (a soluble form 
of the EphB2 extracellular region dimerized by fusion with the 
Fc portion of an antibody) has also been shown to promote 
synapse formation and dendritic spine maturation, presum-
ably through ephrin-B1 and/or ephrin-B2 and a reverse sig-
naling mechanism involving recruitment of the adaptors Grb4 
and GIT1 (Segura et al., 2007).
It will be interesting to further investigate the involvement 
of the Eph system in process extension and synaptogenesis 
of the new neurons that continue to be generated in the hip-
pocampus and the olfactory system throughout life (Chumley 
et al., 2007). In particular, the integration of newly generated 
neurons in the hippocampal circuitry seems to be important 
for the behavioral effects of antidepressants, an area where the 
involvement of Eph receptors has not yet been explored (Sahay 
and Hen, 2007).
Plasticity of Neuronal Circuits
Eph receptors and ephrins persist in the adult brain, particu-
larly in regions where neuronal circuits continue to be remod-
eled in response to environmental changes (Yamaguchi and 
Pasquale, 2004). Indeed, studies with mutant mice have 
shown that the Eph system regulates the plasticity of neu-
ronal connections in structures such as the hippocampus, 
where changes in synapse number and size are important 
for learning and memory. Although the synaptic localization 
of Eph receptors and ephrins has not been fully character-
ized, it is becoming apparent that it may differ depending 
on the brain region and even in different synapses from the 
same neuron (Dalva et al., 2007; Yamaguchi and Pasquale, 
2004). For example, as discussed above, in cortical neu-
rons EphB2 is in spine synapses and ephrin-B3 seems to 
be in shaft synapses. B-type ephrins are presynaptic in area 
CA3 of the mouse hippocampus and the Xenopus optic 
tectum but postsynaptic in area CA1 of the hippocampus. Cell 133, April 4, 2008 ©2008 Elsevier Inc. 41
EphB receptors are also postsynaptic in area CA1, and it 
is unclear whether they are in the same dendritic spines as 
B-type ephrins or in mutually exclusive subpopulations of 
spines. To complicate matters further, EphA4, which is the 
Eph receptor most highly expressed in the adult hippocam-
pus and can interact with all ephrins, has been detected by 
electron microscopy not only in spines but also in presynap-
tic terminals (Tremblay et al., 2007).
Electrophysiological measurements using hippocampal 
slices have demonstrated that the Eph system plays a role 
in paradigms of activity-dependent synaptic plasticity that 
model learning and memory (Dalva et al., 2007; Yamaguchi 
and Pasquale, 2004). These include long-term potentiation 
(LTP), where high-frequency electrical stimulation increases 
synaptic strength; long-term depression (LTD), where low-fre-
quency stimulation reduces synaptic strength; and depoten-
tiation, where low-frequency stimulation reverses the effects 
of LTP. In an initial study, ephrin-A5 Fc treatment caused an 
LTP-like effect whereas EphA Fc inhibited LTP (Yamaguchi 
and Pasquale, 2004). The mechanisms underlying these 
effects, which likely depend on EphA4 and possibly other less 
abundant EphA receptors, remain unclear. EphA4 in the den-
dritic spines of hippocampal neurons has been implicated in 
communication with astrocytes, which express ephrin-A3 on 
their perisynaptic processes. EphA4 activation by ephrin has 
been recently shown to inhibit the Rap1 and Rap2 GTPases 
and integrin activity and to promote RhoA and PLCγ activity 
(Figure 1), causing spine retraction and synapse loss as well 
as changes in spine shape (Bourgin et al., 2007; Fu et al., 
2007; Richter et al., 2007; Zhou et al., 2007). These effects of 
EphA4 forward signaling would be predicted to affect synap-
tic plasticity, perhaps enabling an influence of astrocytes on 
synaptic function.
Electrophysiological measurements have also shown 
reduced LTP and LTD at hippocampal synapses of area CA1 
in EphB2 and EphA4 knockout mice, although basal synaptic 
transmission was normal (Dalva et al., 2007; Yamaguchi and 
Pasquale, 2004). For both receptors, however, knockin mutants 
lacking the kinase domain rescued the defects, suggesting that 
EphB2 and EphA4 forward signaling is not required for these 
forms of synaptic plasticity. Because synaptic plasticity in area 
CA1 depends on postsynaptic mechanisms, EphB2 may regu-
late plasticity by associating with NMDA ion channel recep-
tors and by promoting their synaptic localization. Alternatively, 
EphB2 and/or EphA4 may stimulate reverse signaling through 
postsynaptic ephrins.
Studies with mutant mice have also shown that reverse 
signaling by postsynaptic ephrin-B2 plays an essential role 
in synaptic plasticity in area CA1 of the hippocampus (Bouz-
ioukh et al., 2007; Yamaguchi and Pasquale, 2004). The PDZ 
domain-binding site of ephrin-B2 is required for LTP, LTD, 
and depotentiation, whereas the tyrosine phosphorylation 
sites are only important for LTP. The involvement of eph-
rin-B3 in synaptic plasticity in area CA1 remains to be clari-
fied because different groups have reported either defec-
tive or normal LTP in ephrin-B3 knockout mice (Dalva et al., 
2007). Reverse signaling by presynaptic B-type ephrins has 
been implicated in the regulation of LTP in area CA3, which 42 Cell 133, April 4, 2008 ©2008 Elsevier Inc.depends on presynaptic mechanisms. This effect is due to 
trans-synaptic bidirectional communication with postsynap-
tic EphB2, possibly regulating presynaptic vesicle release. 
Similarly, presynaptic ephrin-B signaling has been recently 
shown to enhance presynaptic glutamate release and post-
synaptic glutamate responsiveness in developing Xenopus 
retinotectal synapses, where EphB2 is also localized post-
synaptically (Lim et al., 2008).
Given the involvement of the Eph system in the regulation 
of dendritic spine morphology and synaptic plasticity, its dys-
function would be predicted to cause learning and memory 
deficits. Indeed, some Eph/ephrin mutations and hippocampal 
infusion of Eph/ephrin Fc fusion proteins have been shown to 
affect learning and memory performance in mice (Dalva et al., 
2007; Yamaguchi and Pasquale, 2004). It will be interesting to 
investigate whether Eph/ephrin dysfunction may cause some 
forms of mental retardation and the accompanying dendritic 
spine abnormalities, and whether downregulation of EphB2 
cell-surface clusters by soluble amyloid β protein has a role 
in the synapse/spine degeneration and memory loss charac-
teristic of Alzheimer's disease (Lacor et al., 2007). Repeated 
exposure to drugs of abuse also causes long-lasting changes 
in the neuronal circuits of certain brain regions, including hip-
pocampus and cortex, and alterations in Eph receptor/ephrin 
expression might contribute to some of these effects (Bahi 
and Dreyer, 2005). Better understanding of how Eph bidirec-
tional signaling regulates synaptic plasticity may suggest new 
strategies to help counteract the cognitive and behavioral 
problems associated with mental retardation, aging, or drug 
addiction.
Repair after Injury
Upregulation of multiple Eph receptors and ephrins has been 
detected at sites of nervous system injury (Du et al., 2007). 
In some cases, developmental expression patterns are reca-
pitulated. In others, new patterns develop under the regula-
tion of cytokines, hypoxia, and other factors present at sites 
of injury. Some of the Eph receptors/ephrins expressed in 
neural cells may provide guidance cues enabling the re-es-
tablishment of appropriate connections, but they may also 
hinder proper axon regrowth through their repulsive signal-
ing (Wu et al., 2007). Eph receptors and ephrins present in 
inflammatory cells and meningeal fibroblasts that infiltrate 
the injury site can also engage in bidirectional signaling 
with Eph proteins upregulated in neural cells, with conse-
quences for regeneration. For example, EphB3 expressed 
in the macrophages recruited to the injured mouse optic 
nerve promotes sprouting of damaged retinal axons, which 
express ephrin-B3 (Liu et al., 2006). Furthermore, the inter-
play between EphB2 expressed in invading meningeal fibro-
blasts and ephrin-B2 expressed in reactive astrocytes after 
rat spinal cord transection appears to promote the segrega-
tion of the two cell types and the formation of the glial scar 
and surrounding basal lamina.
The EphA4 receptor is emerging as an inhibitor of nerve 
regeneration. After lesions to the spinal cord, this recep-
tor accumulates in both damaged corticospinal axons and 
reactive astrocytes (Du et al., 2007; Fabes et al., 2007). 
Analysis of EphA4 knockout mice and infusion of an EphA4 
antagonistic peptide in the intrathecal space surrounding 
the rat spinal cord suggest that EphA4 forward signaling 
plays a role in the axon retraction that occurs after lesion 
and also hinders subsequent axon sprouting/regeneration 
and behavioral recovery. This could be due to interaction 
of axonal EphA4 with both ephrin-B2 expressed in reactive 
astrocytes and ephrin-B3 expressed in myelin. EphA4 in 
reactive astrocytes may also play a role in the formation of 
the glial scar, which forms a barrier impeding axon regen-
eration. According to these still preliminary but intriguing 
studies, strategies to inhibit EphA4 function promise to be 
beneficial for the treatment of spinal cord injury. More exten-
sive studies on the involvement of the Eph system in differ-
ent regions of the central nervous system after various types 
of injury will help identify possible Eph-based strategies to 
improve recovery.
Despite the progress over many years in elucidating the 
activities of Eph bidirectional signaling in neural development, 
plasticity, and repair, new exciting roles continue to be discov-
ered for these molecules. That a single Eph receptor, or eph-
rin, can affect multiple processes through different signaling 
mechanisms underscores how effectively the complexity and 
versatility of the Eph system have been exploited in the ner-
vous system.
Immune Function
Many Eph receptors and ephrins are expressed in lymphoid 
organs and lymphocytes, suggesting that they have immuno-
regulatory properties (Wu and Luo, 2005). For example, the 
Eph system seems to play a role in immune processes where 
cell contact-dependent communication is critical, such as the 
development of thymocytes into mature T cells within the thy-
mus and the subsequent differentiation of activated T cells into 
effector cells in the periphery.
Several studies have shown that perturbing Eph-ephrin 
interactions in thymic organ culture with Eph or ephrin Fc 
fusion proteins interferes with thymocyte survival and matu-
ration (Alfaro et al., 2007; Munoz et al., 2006; Wu and Luo, 
2005). Defects in thymocyte maturation have also been 
observed in EphA4 knockout mice, which have greatly 
decreased numbers of peripheral T cells. These defects 
appear to result from abnormal development of the stromal 
cells of the thymic cortex, which express EphA4 and support 
thymocyte survival and maturation. Preliminary observations 
suggest that EphB2 and EphB3 knockout mice also have a 
disorganized thymic architecture and decreased numbers of 
thymocytes. These findings suggest that the Eph system is 
important for the structural organization of the thymus and 
for guiding the movement of thymocytes through the differ-
ent thymic compartments that support their gradual matura-
tion into T cells.
Other studies have shown that the Eph receptors modulate 
responses mediated by the T cell receptor (TCR) and may rep-
resent a class of costimulatory receptors. EphB6 is the Eph 
receptor whose function in immune regulation has been best 
characterized (Wu and Luo, 2005). This receptor is highly 
expressed in the thymus, where it is present in a substantial 
fraction of thymocytes, particularly those double positive for CD4 and CD8. EphB6 has also been detected in a fraction 
of peripheral CD4+ helper T cells and CD8+ cytotoxic T cells, 
where its levels appear to be dynamically regulated by rapid 
synthesis and removal. Although EphB6 lacks kinase activity, 
stimulation of T cells with anti-EphB6 antibodies or ephrin-B 
ligands leads to increased tyrosine phosphorylation and intra-
cellular signaling. EphB6 phosphorylation may occur through 
association with coexpressed EphB receptors, such as EphB1 
and possibly EphB4. Several cytoplasmic signaling molecules 
known to participate in TCR signaling, such as the adaptor 
and ubiquitin ligase Cbl, associate with EphB6 and have been 
implicated in its effects.
There is substantial evidence that EphB receptors modu-
late T cell responses (Alfaro et al., 2007; Wu and Luo, 2005; 
Yu et al., 2006). First, these receptors cluster with activated 
T cell receptors in aggregated lipid rafts. Second, clustering 
of EphB receptors with immobilized anti-EphB6 antibodies 
or ephrin-B Fc ligands lowers the activation threshold of T 
cells responding to suboptimal TCR ligation. EphB activa-
tion also promotes T cell proliferation, production of inter-
feron γ (but not interleukins 2 and 4), and cytotoxic T cell 
activity. These effects involve upregulation of the p38 and 
p42/44 MAP kinases. Third, EphB6-negative T cells purified 
from human peripheral blood or from the spleen of EphB6 
knockout mice show impaired TCR signaling, proliferation, 
and cytokine secretion in vitro. Fourth, the EphB6 knock-
out mice show impaired cellular immune responses despite 
having normal T cell numbers. Thus, EphB receptor ligation 
enhances the effects of weak TCR signaling, suggesting that 
EphB receptors promote positive thymocyte selection and 
T cell responses to antigen-presenting cells. On the other 
hand, in thymocytes and Jurkat T cells EphB receptor sig-
naling has also been reported to blunt the effects of high 
TCR signaling, such as interleukin-2 secretion and induc-
tion of apoptosis. Hence, EphB receptor ligation might also 
inhibit the effects of strong TCR signaling, such as the nega-
tive selection of self-reactive thymocytes.
Physiologically, EphB receptors in T cells are likely acti-
vated through interactions with ephrin-B ligands expressed 
by other T cells as well as other cell types, such as thymic 
epithelial cells and antigen-presenting cells (Wu and Luo, 
2005). Interestingly, these Eph interactions may facilitate T 
cell responses in lymphoid organs, where T cells and anti-
gen-presenting cells have sustained contact to promote dif-
ferentiation of naive T cells into effectors.
EphA receptors and A-type ephrins are also expressed in 
thymocytes and T cells (Freywald et al., 2006; Wu and Luo, 
2005) and have also been reported to modulate TCR signal-
ing. For example, stimulation of CD4+ CD8+ double-positive 
thymocytes with ephrin-A1 Fc inhibits interleukin-2 secretion 
and apoptosis induced by strong TCR activation. This sug-
gests that EphA receptors modulate negative selection of 
self-reactive thymocytes, which depends on apoptosis trig-
gered by strong TCR stimulation. Ephrin-A1 is also expressed 
in CD4+ helper T cells, where it may have a functional effect 
through reverse signaling because its ligation with antibod-
ies has been reported to suppress TCR responses. Further-
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thymocyte and T cell migratory responses to chemokines 
(such as SDF1) and integrin-dependent adhesion, which 
guide thymocyte movements within the thymus and T cell 
trafficking between the blood, lymphoid tissues, and sites 
of extravasation (Hjorthaug and Aasheim, 2007; Sharfe et 
al., 2008; Wu and Luo, 2005). Signaling molecules that have 
been implicated in EphA-dependent regulation of T cell 
migration include the cytoplasmic tyrosine kinases Lck and 
Pyk2, the exchange factor Vav1, and Rho family GTPases. 
However, more work is needed to establish the physiological 
significance of the EphA-dependent chemotactic and adhe-
sive responses observed in vitro.
Eph receptors and ephrins are also expressed in B lym-
phocytes, but their effects in these cells have not been 
characterized (Aasheim et al., 2000; Nakanishi et al., 2007). 
Clearly, more work is needed to refine our knowledge of Eph 
bidirectional signaling in the immune system. As in other 
organs, the role of these molecules is likely to be complex 
and involve the coordinated activities of different Eph recep-
tors and ephrins that have intertwined and partially overlap-
ping functions. Careful expression studies and evaluation of 
immunological defects in compound Eph and ephrin condi-
tional knockout mice will be particularly useful for dissecting 
these roles. It will also be important to determine whether 
defects in Eph function contribute to immunological disor-
ders and hematopoietic malignancies where Eph proteins 
are highly expressed (Nakanishi et al., 2007).
Glucose Homeostasis and Diabetes
The β cells in the pancreas adjust their secretion of insulin in 
response to glucose levels in the blood in order to maintain 
glucose homeostasis in the body. Communication between 
β cells clustered in pancreatic islets has long been known 
to modulate insulin secretion, but the underlying molecular 
mechanisms were unknown. A recent study using cultured 
cells and mouse models shows that β cells communicate 
via EphA receptors and ephrin-A ligands (Konstantinova et 
al., 2007). Remarkably, EphA forward signaling (which inhib-
its insulin secretion) and ephrin-A reverse signaling (which 
enhances insulin secretion) can be differentially regulated in 
pancreatic cells (Figure 3). When glucose is low, EphA for-
ward signaling predominates, decreas-
ing basal insulin secretion. Glucose 
causes EphA receptor dephosphory-
lation, leading to downregulation of 
EphA forward signaling without inhi-
bition of ephrin-A reverse signaling. 
Thus, reverse signaling predominates when glucose is high, 
increasing insulin secretion. A further twist is that although 
ephrin-A ligands are mainly localized on the plasma mem-
brane, EphA receptors are also in the intracellular insulin 
secretory granules. This suggests that EphA levels on the 
plasma membrane, and therefore EphA-ephrin-A com-
plexes, increase upon insulin release. This causes a negative 
feedback loop that limits insulin secretion through increased 
EphA signaling when glucose levels are low and a positive 
feedback loop that potentiates secretion through increased 
ephrin-A signaling when glucose levels are high (Figure 3).
Although further studies will be required to fully eluci-
date the signaling pathways underlying these effects, some 
evidence suggests that the opposite effects of EphA and 
ephrin-A signaling depend on differential regulation of Rac1 
GTPase activity and actin filament assembly as well as gap 
junction communication. A number of intriguing questions 
also remain. First, do EphB receptors and ephrin-B ligands—
which are also expressed in pancreatic β cells—contribute 
to the regulation of glucose homeostasis or have other 
functions? Second, do these results in the pancreas reveal 
a general mechanism by which Eph receptors and ephrins 
regulate exocytosis in other secretory systems? Third, do 
the Eph-dependent defects in insulin secretion play a role in 
type 2 diabetes and might the ability of the EphA/ephrin-A 
system to affect insulin release be exploited in the treatment 
of diabetes?
Bone Maintenance and Bone Remodeling Diseases
Developmental deficiencies in EphB/ephrin-B signaling can 
cause skeletal malformations. These include cleft palate, 
defective development of the skull vault, craniosynostosis, 
and other bone abnormalities observed in EphB2/EphB3 
and ephrin-B1 mutant mice and in individuals harboring 
ephrin-B1 mutations that cause the X-linked developmen-
tal disorder craniofrontonasal syndrome (Davy et al., 2006; 
Pasquale, 2005). Interestingly, mosaic ephrin-B1 expression 
in calvarial osteoblast precursors—due to random X chro-
mosome inactivation in ephrin-B1 heterozygous females—
causes abnormal cell sorting leading to defects in bone 
development. Genetic and other evidence supports a model 
Figure 3. EphA-Ephrin-A Bidirectional  
Signaling and Insulin Secretion
When glucose levels are low, forward signaling 
predominates inhibiting insulin secretion; when 
glucose levels are high, reverse signaling pre-
dominates promoting insulin secretion. Ephrin-A 
molecules are mainly on the cell surface whereas 
Eph receptor molecules are also in the secretory 
granules. Thicker lines indicate stronger signals; 
yellow circles, tyrosine phosphorylation.44 Cell 133, April 4, 2008 ©2008 Elsevier Inc.
in which EphB-ephrin-B1 bidirectional signaling at the ecto-
pic boundaries that form between ephrin-B1 positive and 
negative osteoblast precursors leads to impaired gap junc-
tion communication, which inhibits osteoblast differentiation 
and delays ossification of developing calvarial bones.
Besides these developmental roles, EphB-ephrin-B bidi-
rectional signaling between osteoblasts and osteoclasts has 
been implicated in the regulation of bone homeostasis in the 
adult (Zhao et al., 2006). Bones continue to be remodeled 
throughout life, a process controlled by dynamic reciprocal 
communication between osteoclasts, which degrade bone, 
and osteoblasts, which form bone. Gain- and loss-of-function 
experiments in culture have shown that cytokines produced 
by osteoblasts activate the transcription factors c-Fos and 
NFATc1 in osteoclast precursors. This promotes osteoclast 
differentiation and also increases ephrin-B2 expression 
(Figure 4). Several Eph receptors present in osteoblasts can 
stimulate ephrin-B reverse signaling in osteoclasts, which 
represses osteoclast differentiation through a negative 
feedback loop that inhibits c-Fos and NFATc1 and requires 
the ephrin PDZ domain-binding site.
The communication between osteoclasts and osteoblasts 
is bidirectional and forward signaling by EphB4—and pos-
sibly other coexpressed Eph receptors—promotes the dif-
ferentiation of osteoblasts, which deposit new bone at sites 
of resorption by osteoclasts (Figure 4). The Eph forward 
signaling pathway responsible for osteoblast differentiation 
may involve RhoA inactivation. Hence, cell contact-depen-
dent communication between Eph receptors and ephrins 
limits osteoclast differentiation and enhances osteoblast 
differentiation, inducing a shift from bone resorption to 
bone formation. Indeed, transgenic overexpression of 
EphB4 in osteoblasts has been shown to increase bone 
mass in mice.
These findings suggest that interventions targeting the 
EphB system may be helpful in the prevention and treatment 
of bone remodeling diseases, such as osteoporosis and 
osteopetrosis. It will be important, however, to elucidate the 
role of bidirectional signaling between osteoblasts, which 
in addition to EphB receptors also express B-type ephrins. 
Another unresolved issue with possible therapeutic impli-
cations is whether Eph-ephrin interactions between cancer 
cells and osteoblasts or osteoclasts may play a role in bone 
metastatic disease.
Intestinal Homeostasis
The intestine is lined by a monolayer of 
epithelial cells that control the absor-
bance of nutrients and the secretion 
of protective mucus and antimicrobial 
agents. The intestinal epithelium undergoes continuous self-
renewal throughout life, and homeostasis is maintained by the 
balance of cell proliferation, differentiation, and apoptosis. A 
recent study has shown that a few cycling cells located at the 
bottom of invaginations called crypts can generate all intesti-
nal epithelial lineages and therefore likely represent the long 
sought-after intestinal stem cells (Barker et al., 2007). The stem 
cells give rise to rapidly proliferating transit-amplifying cells, 
which differentiate while migrating toward the top of the crypts. 
In the small intestine, epithelial cells continue to migrate toward 
the tips of protrusions called villi, where they die and are shed 
into the intestinal lumen.
The canonical Wnt/β-catenin/Tcf signaling pathway is a criti-
cal regulator of homeostasis in the intestinal epithelium, in part 
through its ability to promote the transcription of EphB recep-
tors and inhibit that of ephrin-B ligands (Clevers and Batlle, 
2006). As the newly generated epithelial cells migrate, they 
gradually lose EphB expression and acquire ephrin-B expres-
sion as they move away from the source of Wnt secreted by 
surrounding mesenchymal cells at the bottom of the crypts. 
This creates countergradients of EphB and ephrin-B expres-
sion along the crypt axis, with high EphB expression at the 
bottom of the crypts and high ephrin-B expression at the top 
and in the villi. A population of secretory cells in the small intes-
tine, called Paneth cells, also undergoes renewal but remains 
interspersed with the stem cells at the bottom of the crypts. 
Unlike other intestinal epithelial cells, Paneth cells can dif-
ferentiate when Wnt levels are high. They also maintain high 
EphB3 expression after differentiation, which is important for 
their localization.
Analysis of EphB2/EphB3 and ephrin-B1 knockout mice, and 
knockin mice expressing a dominant-negative form of EphB2 
replacing the wild-type receptor, has shown that EphB-depen-
dent repulsive signaling restricts intermingling of the proliferat-
ing and differentiated cells (Clevers and Batlle, 2006; Cortina 
et al., 2007). Interestingly, crosstalk with E-cadherin appears to 
play a crucial role (Figure 2). EphB forward signaling promotes 
E-cadherin-mediated cell adhesion in colorectal cancer cells, 
and E-cadherin is required for the in vitro sorting of EphB- and 
ephrin-B-expressing cells into separate cell clusters.
Perturbation of EphB forward signaling in the mouse 
through genetic manipulations or administration of soluble 
forms of the ephrin-B2 or EphB2 extracellular domains has 
also implicated the EphB system in intestinal epithelial cell 
Figure 4. EphB-Ephrin-B Bidirectional Sig-
naling in Bone Formation
Osteoblasts secrete cytokines that upregulate 
ephrin-B2 in osteoclast precursors. Ephrin-B li-
gands in osteoclasts interact with EphB receptors 
in osteoblasts generating bidirectional signals that 
inhibit osteoclast differentiation and promote os-
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proliferation (Holmberg et al., 2006). Cell proliferation was 
decreased on the sides of the crypts and not at the bottom, 
suggesting that the EphB system promotes the proliferation 
of transit-amplifying cells.
It will be important to also examine the role of the EphA/
ephrin-A system in intestinal homeostasis because uneven 
mRNA expression along the crypts of the colon has also been 
reported for several EphA receptors and ephrin-A1 (Kosinski 
et al., 2007). EphA2 and ephrin-A1 have also been suggested 
to regulate epithelial barrier function in the intestine (Rosen-
berg et al., 1997). Future studies to explore whether Eph recep-
tors and ephrins may play a role in intestinal diseases, such 
as inflammatory bowel disease, or in the restoration of the 
injured intestinal epithelium (Hafner et al., 2005; Rosenberg et 
al., 1997) will provide a more complete understanding of the 
Eph system in intestinal homeostasis and disease. The EphB 
system has also been implicated in colorectal cancer (see next 
section). The Eph bidirectional signaling pathways in normal 
and transformed intestinal epithelial cells also await a compre-
hensive investigation.
Cancer
Besides their expression in normal tissues, Eph receptors 
and/or ephrins are present, and often upregulated, in essen-
tially all types of cancer cells (Ireton and Chen, 2005; Noren 
and Pasquale, 2007). In many cases this may be due to onco-
genic signaling pathways, hypoxia, or inflammatory cytokines. 
For example, the Wnt/β-catenin/Tcf pathway promotes EphB 
expression in colorectal cancer cells and the Ras-MAP kinase 
pathway promotes EphA2 expression in breast cancer cells. 
Interestingly, activation of these two pathways also results in 
ephrin downregulation and, as a consequence, low Eph receptor 
activation. Indeed, Eph receptor forward signaling does not nec-
essarily aid the tumorigenic process. Tumor suppressor activi-
ties have been reported for Eph signaling in colorectal, breast, 
prostate, and skin cancer cells both in vitro and in vivo. How-
ever, the decreased tumorigenicity of cancer cells in which Eph 
receptor expression was experimentally decreased suggests 
that these receptors can also have tumor-promoting effects. 
The role of ephrin reverse signaling in cancer cells is poorly 
characterized, although several ephrins have been reported to 
promote cell transformation and cancer cell migration/invasion 
(Campbell et al., 2006; Meyer et al., 2005; Tanaka et al., 2007). To 
complicate matters further, the Eph system is also operational in 
the tumor microenvironment. The effects of Eph-ephrin bidirec-
tional signaling have been mostly studied in tumor endothelial 
cells, whereas information on other types of tumor stromal cells 
is very limited. In order to design rational strategies to target 
the Eph system for cancer therapy, we need to further elucidate 
how Eph receptors and ephrins influence the behavior of cancer 
cells, cancer stromal cells, and also cancer stem cells. Below we 
discuss work on several cancers, which exemplifies our current 
understanding of the Eph system in oncogenic transformation.
Colorectal Cancer
The same signaling proteins that control physiological self-re-
newal in the intestine can also initiate malignant transformation 
when mutations subvert their activity. Thus, constitutive activa-
tion of the Wnt/β-catenin/Tcf pathway leads to the formation of 46 Cell 133, April 4, 2008 ©2008 Elsevier Inc.adenomas and colorectal cancer (Clevers and Batlle, 2006). 
As in the normal intestine, the pathway also upregulates EphB 
expression in the early stages of tumorigenesis. Despite their 
reported ability to promote proliferation in the intestinal epithe-
lium, the EphB receptors appear to have a tumor suppressor 
role in colorectal cancer. Indeed, in advanced human colorec-
tal cancers expression of different EphB receptors is lost in a 
large fraction of the tumor cells, and there is strong associa-
tion of tumor histological grade and patient survival with EphB 
silencing (Batlle et al., 2005). Intriguingly, hypoxia may explain 
the coordinated downregulation of multiple EphB receptors 
in advanced cancers because hypoxia-inducible factor-1 can 
compete with Tcf-4 for binding to nuclear β-catenin, leading to 
silencing of Tcf-4 target genes (Kaidi et al., 2007).
Reduced EphB activity accelerates the progression of col-
orectal cancer. This is supported by studies with the ApcMin/+ 
mouse model, where poorly differentiated and aggressive col-
orectal adenocarcinomas develop in mice lacking EphB3 or 
ephrin-B1 and in mice expressing dominant-negative EphB2 
but not in control mice (Batlle et al., 2005; Cortina et al., 2007). A 
possible mechanism inhibiting the expansion of EphB-positive 
tumor cells involves E-cadherin-dependent spatial restriction 
by surrounding epithelial cells that express ephrin-B ligands. 
The involvement of the EphA/ephrin-A system in colorectal 
cancer remains to be investigated using mouse models, to fol-
low up on cell culture studies suggesting oncogenic effects 
of coexpressed EphA2 and ephrin-A1 (Wimmer-Kleikamp and 
Lackmann, 2005).
Breast Cancer
EphA2 and EphB4 are the Eph receptors most extensively 
studied in breast cancer, although our understanding of 
their activities is far from complete (Ireton and Chen, 2005; 
Macrae et al., 2005; Noren and Pasquale, 2007). Both recep-
tors are widely expressed but poorly tyrosine phosphory-
lated in human breast cancer cell lines, suggesting a low 
level of ephrin-dependent activation. Indeed, the levels of 
ephrin-B2—the preferred ligand for EphB4—are low in these 
cell lines, and high EphA2 expression also correlates with 
low ephrin-A expression. Intriguingly, even when ephrin-A1 
is present, its ability to activate EphA2 may be impaired in 
breast cancer cells that lack E-cadherin. These data suggest 
that if EphA2 and EphB4 have oncogenic activity in human 
breast cancer cell lines, this activity must be either inde-
pendent of ephrin stimulation or manifest itself when ephrin 
stimulation is low.
Overexpression of EphA2 in a human mammary epithelial 
cell line has been shown to cause oncogenic transformation 
(Ireton and Chen, 2005; Noren and Pasquale, 2007). Despite 
the fact that EphA2 was poorly tyrosine phosphorylated, the 
overexpressing cells acquired the ability to grow in soft agar 
and form tumors in mice. Furthermore, they had decreased 
estrogen dependence and sensitivity to the drug tamoxifen. On 
the other hand, EphA2 knockdown by RNA interference or with 
antisense oligonucleotides has been shown to inhibit the tum-
origenicity of several types of cancer cells, including a breast 
cancer cell line. Similarly, EphB4 knockdown inhibited breast 
cancer cell survival, migration, and invasion, and also tumor 
growth in a mouse xenograft model.
The mechanisms underlying these oncogenic effects of 
Eph receptors that appear to be poorly activated are unclear. 
Some evidence suggests that ephrin-independent crosstalk 
with oncogenic signaling pathways may be involved. For 
example, EphA2 has been found to enhance tumor cell pro-
liferation and motility in cells overexpressing EGF receptor 
family members, an activity that likely contributes to tum-
origenesis and metastatic progression in a mouse ErbB2 
mammary adenocarcinoma model (Brantley-Sieders et al., 
2008; Larsen et al., 2007). The Eph receptors might also 
serve as scaffolds for constitutively associated signaling 
proteins, somehow affecting their localization and signaling 
ability to promote cell transformation. One study has shown 
that when transformed by EphA2 overexpression, mammary 
epithelial cells deposit more fibronectin, which plays a role 
in their survival (Hu et al., 2004). Oncogenic signaling path-
ways that may be activated by low ephrin levels could also 
be responsible for the tumorigenic effects of EphA2 and 
EphB4 in breast cancer cells.
Low versus high Eph forward signaling might have oppo-
site effects on tumorigenicity, as has been shown for other 
cellular properties (Pasquale, 2005; Poliakov et al., 2004). 
EphA2 dephosphorylation by the low-molecular-weight 
phosphotyrosine phosphatase has been shown to promote 
mammary epithelial cell transformation, presumably by 
inhibiting EphA2 forward signaling (Noren and Pasquale, 
2007; Wimmer-Kleikamp and Lackmann, 2005). Furthermore, 
EphA2 and EphB4 activation with soluble ephrin ligands or 
activating antibodies decreases the malignant properties of 
human breast cancer cell lines. Activation of EphA2 inhib-
ited growth in soft agar, fibronectin deposition, cell survival, 
and tumor growth in a breast cancer xenograft model (Ireton 
and Chen, 2005). Inhibition of Ras activity downstream of 
EphA2 likely plays an important role in these tumor suppres-
sor effects by inhibiting downstream MAP kinases and pos-
sibly also the PI3 kinase-Akt pathway (Figure 5) (Menges and 
McCance, 2007). EphB4 activation also inhibits breast can-
cer cell growth and migration (Noren and Pasquale, 2007). 
These effects involve activation of Abl 
family tyrosine kinases and tyrosine 
phosphorylation of the adaptor protein 
Crk, likely inhibiting Rac activity (Fig-
ure 1B). Curiously, high levels of ephrin 
stimulation produce effects similar to 
EphA2 or EphB4 knockdown in cultured 
breast cancer cells. Further studies are 
needed to elucidate the mechanisms 
underlying the antioncogenic effects of 
ephrin stimulation versus downregula-
tion of Eph receptor expression.
A possible working hypothesis is that high levels of eph-
rin-dependent EphA2 and EphB4 forward signaling sup-
press tumorigenesis whereas low levels of forward signal-
ing or crosstalk with oncogenic signaling pathways promote 
tumorigenicity. However, in contrast to its tumor suppressor 
effects in human breast cancer cells, EphA2 kinase activity 
appears to promote tumorigenesis in mouse 4T1 mammary 
tumor cells, which express ephrin-A1 (Brantley-Sieders et 
al., 2006). In these cells, EphA2 kinase activity promotes 
VEGF secretion, RhoA activation, and cell motility in vitro 
as well as tumor growth and metastasis in mouse models. 
EphA2 is also tyrosine phosphorylated and coexpressed with 
ephrin-A1 in other types of cancer cells, including malignant 
melanoma cells, suggesting divergent roles for EphA2 in 
cell transformation depending on the cellular context (Ireton 
and Chen, 2005). Perhaps, cancer cells that endogenously 
express highly activated Eph receptors have evolved mech-
anisms to neutralize their tumor suppressor signals. For 
example, Ras- and Raf-activating mutations could counter-
act some of the antioncogenic effects of activated EphA2 
(Figure 5) (Menges and McCance, 2007).
Skin Cancer and Melanoma
The most common types of skin cancer are derived from 
either melanocytes or keratinocytes, and EphA2 appears 
to have different effects in the two types of cancer cells. 
In melanoma, ephrin-A1-mediated activation of EphA2 and 
possibly other EphA receptors promotes proliferation (Easty 
and Bennett, 2000; Hess et al., 2007). Intriguingly, EphA2 
has also been found to associate with vascular endothe-
lial cadherin and promote the formation of blood vessel-
like structures by malignant melanoma cells, a role similar 
to that of EphA2 in tumor endothelial cells (see below). In 
contrast, a recent study has shown that susceptibility to 
chemically induced keratinocyte transformation is enhanced 
in EphA2 knockout mice (Guo et al., 2006). Furthermore, 
despite the observed upregulation of EphA2 in mouse as 
well as human keratinocyte-derived skin carcinomas, the 
tumors lacking EphA2 grow faster and are more invasive. 
Figure 5. EphA2, Cell-Cycle Arrest, and  
Cellular Senescence
Raf-activating mutations upregulate the levels of 
EphA2, which may contribute to cell-cycle arrest 
and senescence through inhibition of H-Ras-PI3 
kinase-Akt. In cells without activated Raf, EphA2 
also inhibits the MAP kinase pathway.Cell 133, April 4, 2008 ©2008 Elsevier Inc. 47
Similar to the EphB/ephrin-B interplay in colorectal cancer, 
ephrin-A1 expression in the surrounding skin appears to 
restrict expansion of the EphA2-positive tumor cells. Inhibi-
tion of Ras-dependent pathways may explain these tumor 
suppressor effects of EphA2.
Bidirectional signaling through other Eph receptors and 
ephrins can also have diverse effects on melanoma malig-
nancy. For example, EphB4 activation by coexpressed 
ephrin-B2 in the aggressive SW1 mouse melanoma cell line 
promotes RhoA activation, leading to increased ameboid 
migration (Noren and Pasquale, 2007). In contrast, EphB4 
activation with ephrin-B2 Fc in the human MDA-MB-435 
cell line (which has low endogenous ephrin-B2 expression) 
inhibits proliferation, survival, migration, and invasion in 
vitro as well as tumor growth in a mouse xenograft model 
through a pathway involving Abl and Crk. It should be noted 
that a recent study provides strong evidence that the cur-
rently available stocks of MDA-MB-435 cells, which were 
previously believed to be of breast cancer origin, are instead 
derived from a melanoma line (Rae et al., 2007).
In addition to promoting EphB signaling, endogenous 
ephrin-B2 expressed in melanoma cells has also been 
found to associate with β1-integrins and promote cell adhe-
sion and migration, suggesting a role in tumor progression 
through reverse signaling and crosstalk with integrins (Fig-
ure 2) (Meyer et al., 2005). The EphA4 receptor is expressed 
in melanocytes but downregulated in aggressive melanoma 
cells, suggesting that EphA4 has a role as a melanoma tumor 
suppressor (Easty and Bennett, 2000). EphB6 is also down-
regulated during melanoma progression, but this receptor 
lacks kinase activity and thus may function differently from 
other Eph receptors (Hafner et al., 2003).
Tumor Angiogenesis
Besides being expressed in cancer cells, Eph receptors and 
ephrins are also present in the tumor vasculature, where they 
promote angiogenesis (Brantley-Sieders and Chen, 2004; Her-
oult et al., 2006; Noren and Pasquale, 2007). Because blood 
vessels are critical for tumor growth and metastasis, this is 
an important aspect of the oncogenic effects of Eph-ephrin 
bidirectional signaling. The main roles in tumor angiogenesis 
have so far been attributed to EphA2 forward signaling and 
ephrin-B2 reverse signaling based on a series of in vitro and in 
vivo experiments with mouse tumor models, including analy-
sis of angiogenesis in EphA2 knockout mice. Interestingly, 
EphA2 is not expressed in the embryonic vasculature or the 
adult quiescent vasculature. Interaction with ephrin-A1 present 
in tumor endothelial cells as well as tumor cells is responsible 
for activating endothelial EphA2. Signaling effectors that have 
been implicated in the angiogenic activity of EphA2 include PI3 
kinase, Vav guanine nucleotide exchange factors, and Rac1 
(Figure 1B). Activation of these effectors presumably impacts 
the actin cytoskeleton, thus regulating endothelial cell shape 
and migration. Interestingly, EphA2 appears to be required for 
VEGF-induced endothelial cell migration and assembly into 
capillary-like structures (Chen et al., 2006).
Ephrin-B2 is also widely expressed in the vasculature of 
many tumors, which is not surprising given that this ephrin 
is found in the embryonic arterial vasculature and its expres-48 Cell 133, April 4, 2008 ©2008 Elsevier Inc.sion in endothelial cells is upregulated by hypoxia and VEGF 
(Brantley-Sieders and Chen, 2004; Heroult et al., 2006; Noren 
and Pasquale, 2007). Ephrin-B2 reverse signaling can be 
stimulated by interaction with EphB4 expressed in the tumor 
vasculature and in tumor cells. Indeed, increased levels of 
the EphB4 extracellular portion on the surface of a cancer 
cell line have been shown to increase tumor growth through 
effects on the vasculature. EphB4 activation by ephrin-B2 in 
circulating endothelial progenitor cells also increases their 
recruitment to sites of neovascularization through selectin-
mediated adhesion (Foubert et al., 2007). It will be interest-
ing to investigate whether this also contributes to tumor neo-
vascularization.
Given the divergent effects of Eph receptors and ephrins 
in cancer cells, Eph-based anticancer therapies involving 
vascular targeting seem the most straightforward. Indeed, 
various approaches to interfere with EphA2-ephrin-A or 
EphB-ephrin-B2 binding using soluble Eph extracellular 
domains have consistently resulted in inhibition of tumor 
growth in various mouse models (Heroult et al., 2006; Ire-
ton and Chen, 2005; Noren and Pasquale, 2007; Wimmer-
Kleikamp and Lackmann, 2005). However, targeting the Eph 
system will also affect the tumor cells, likely with variable 
outcomes depending on the tumor type. Ultimately, the effi-
cacy of each Eph-based targeting strategy will have to be 
evaluated empirically in appropriate in vivo tumor models.
Cancer Stem Cells
An emerging theme in cancer therapy is the possible importance 
of targeting the “cancer stem cells,” which are the cells that can 
repopulate the tumor and cause recurrence even when most of 
the tumor mass has been eliminated. Because Eph receptors/
ephrins are expressed in various other types of stem cells, they 
are also likely to be present in cancer stem cells (Pasquale, 2005). 
However, characterization of the Eph system in stem cells is still 
at an early stage. Positive as well as negative effects on prolifera-
tion, apoptosis, and differentiation have been reported depending 
on the Eph/ephrin involved and the type of stem cell. An area of 
particular interest is the role of Eph-ephrin bidirectional signal-
ing in the communication between stem cells and their support-
ing niche cells. Intriguingly, a recent study has implicated Eph 
receptor-dependent inhibition of the Ras-MAP kinase pathway in 
the asymmetric division of at least two different precursor cells 
in the ascidian embryo (Picco et al., 2007; Shi and Levine, 2008). 
It was shown that contact with asymmetrically localized ephrin-
expressing neighboring cells triggers polarized Eph receptor 
activity, driving specification of one of the two daughter cells to a 
neural rather than notochord fate or to a mesodermal rather than 
an endodermal fate. It will be interesting to investigate whether 
Eph-ephrin interactions with niche cells might have a similar role 
in the self-renewal versus differentiation choice during asymmet-
ric stem cell division. Knowing the effects of Eph-ephrin signaling 
in cancer stem cells will likely be important in deciding how to 
target these molecules for anticancer therapy.
Henipavirus Infection
It was recently discovered that ephrin-B2 and ephrin-B3 serve 
as the cell entry receptors for Nipah and Hendra viruses, two 
emerging paramyxoviruses comprising the newly defined 
Henipavirus genus (Bonaparte et al., 2005; Negrete et al., 
2005, 2006). Although the natural host for henipaviruses is 
the fruit bat, outbreaks in farm animals and transmission to 
humans have repeatedly occurred in recent years. The high 
evolutionary conservation of the ephrins explains the abil-
ity of Nipah and Hendra viruses to infect a wide range of 
animal species. In humans, these viruses are highly lethal 
and are classified as category 4 containment pathogens. 
The tissue distribution of ephrin-B2 in the vascular system 
and both ephrin-B2 and ephrin-B3 in the nervous system are 
consistent with the tissue tropism of the viruses. Both Nipah 
and Hendra viruses bind to the same region of ephrin-B2 
and ephrin-B3 that also mediates high-affinity binding to 
EphB receptors. It will therefore be interesting to determine 
whether disruption of EphB/ephrin-B function, or activation 
of reverse signals following ephrin-B clustering by the tetra-
meric viral attachment glycoprotein, play a role in disease 
pathogenesis. From a therapeutic perspective, it will also 
be important to determine if soluble forms of the ephrin-B2 
and EphB4 extracellular domains, which inhibit henipavirus 
infection in cell culture, may also be useful as prophylactic 
agents. Furthermore, various soluble forms of the henipa-
virus G protein, which binds ephrin-B2 with subnanomolar 
affinity, may have therapeutic applications to stimulate or 
inhibit angiogenesis, depending on their ability to activate or 
block reverse signaling.
Concluding Remarks
Additional roles of Eph receptors and ephrins in adult physi-
ology beyond those discussed in the previous sections have 
been discovered, and the list continues to grow. For exam-
ple, hypoxia reportedly stimulates upregulation of ephrin-B2 
in bone marrow stromal cells, which in turn activates EphB4 
signaling in hematopoietic progenitor cells (Pasquale, 2005). 
This causes the detachment of the progenitor cells from the 
stroma and their differentiation into red blood cells, sug-
gesting an Eph-dependent mechanism to maintain oxygen 
homeostasis in the blood. An involvement of the Eph system 
in blood clotting has also been demonstrated, where EphA4 
and ephrin-B1 expressed in human platelets contribute to 
the stabilization of the blood clot through an integrin-de-
pendent mechanism (Arvanitis and Davy, 2008). Eph/eph-
rin-dependent regulation of the permeability of intercellular 
junctions likely plays a role in glomerular filtration in the kid-
ney. In particular, ephrin-B1 has been recently identified as 
a potentially important component of the slit diaphragm of 
podocytes (Hashimoto et al., 2007). Analysis of mutant mice 
has revealed that EphB2-ephrin-B2 bidirectional signaling 
controls the ionic homeostasis of the vestibular endolymph 
fluid in the inner ear and, therefore, has a potential role in 
vertigo and positional nystagmus (Dravis et al., 2007). Fur-
thermore, given that several Eph receptors and ephrins are 
expressed in inflammatory cells and upregulated by inflam-
matory cytokines, the Eph system likely has multiple roles 
in inflammation (Ivanov and Romanovsky, 2006). EphB-eph-
rin-B interactions have also been implicated in the develop-
ment of chronic neuropathic pain following tissue damage 
(Du et al., 2007). It can be expected that new discoveries clarifying the mechanisms of the known and yet to be dis-
covered Eph physiological activities will keep the spotlight 
on the Eph field for years to come.
However, several factors could accelerate progress. It is 
becoming apparent that expression of Eph receptors and 
ephrins undergoes dynamic spatial and temporal regulation 
at the transcriptional and posttranscriptional levels, not only 
during development but also in the adult and probably in 
diseased tissues. Knowing the relative abundance and cel-
lular localization of Eph receptors and ephrins, and their 
subcellular localization, is critical for understanding biologi-
cal function. Therefore, to determine precisely which Eph 
receptors or ephrins are involved in a particular physiologi-
cal process, or should be targeted in a particular disease, 
there is an urgent need for validated and specific antibodies 
that will enable detailed expression studies. It is also becom-
ing clear that Eph receptors and ephrins can use multiple 
signaling mechanisms to achieve different effects and that 
their downstream pathways are often intertwined with other 
signaling networks. The availability of conditional knockout 
mice where gene inactivation can be spatially and tempo-
rally regulated, and of knockin mice in which a mutated 
Eph/ephrin replaces the wild-type protein, will be critical 
for understanding physiological functions and elucidating 
the in vivo importance of particular downstream signaling 
pathways. Functional antibodies and chemical genetics 
approaches also hold great promise for moving the field for-
ward, particularly as more antibodies, peptides, and chemi-
cal compounds that can selectively modulate the function 
of individual Eph receptors and ephrins become available 
(Himanen et al., 2007; Noren and Pasquale, 2007; Pasquale, 
2005). These tools also have the potential to be used for the 
selective targeting of only a particular Eph/ephrin domain, 
thus enabling a detailed mechanistic characterization of 
the multiple activities of these proteins. Systems biology 
approaches to integrate Eph signaling pathways with other 
signaling networks will also be helpful. A thorough under-
standing of Eph-ephrin bidirectional activities will provide 
new perspectives on physiology, disease pathogenesis, and 
potential therapies.
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